{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:21:47Z","timestamp":1783948907459,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejrad.2020.109275","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T11:34:54Z","timestamp":1599737694000},"page":"109275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors"],"prefix":"10.1016","volume":"132","author":[{"given":"Hyesun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Hatabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiya J.","family":"Aijazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-0502","authenticated-orcid":false,"given":"Mizuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2020.109275_bib0005","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejrad.2020.109275_bib0010","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.21037\/jtd.2017.11.52","article-title":"New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases","volume":"9","author":"Dayen","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejrad.2020.109275_bib0015","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","article-title":"Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without Bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial","volume":"35","author":"Tiseo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0020","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0030","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2020.109275_bib0035","unstructured":"Administration USFaD. FDA approves atezolizumab for extensive-stage small cell lung cancer. Available from URL: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer [accessed June 22, 2019]."},{"key":"10.1016\/j.ejrad.2020.109275_bib0040","unstructured":"Administration USFaD. FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer. Available from URL: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-nivolumab-accelerated-approval-third-line-treatment-metastatic-small-cell-lung-cancer [accessed June 22, 2019]."},{"key":"10.1016\/j.ejrad.2020.109275_bib0045","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00261-019-01935-2","article-title":"Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor","volume":"44","author":"Alessandrino","year":"2019","journal-title":"Abdom. Radiol. (NY)"},{"key":"10.1016\/j.ejrad.2020.109275_bib0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31","author":"Kim","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejrad.2020.109275_bib0055","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","author":"Kim","year":"2013","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0060","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejrad.2020.109275_bib0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejrad.2020.109275_bib0070","doi-asserted-by":"crossref","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","article-title":"Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients","volume":"10","author":"Remon","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ejrad.2020.109275_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1148\/radiol.2018181349","article-title":"Imaging of cancer immunotherapy: current approaches and future directions","volume":"290","author":"Nishino","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2020.109275_bib0080","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejrad.2020.109275_bib0085","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-Related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2020.109275_bib0090","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1148\/rg.2017170015","article-title":"Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care","volume":"37","author":"Nishino","year":"2017","journal-title":"Radiographics."},{"key":"10.1016\/j.ejrad.2020.109275_bib0095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","article-title":"Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer","volume":"4","author":"Nishino","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejrad.2020.109275_bib0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial","volume":"53","author":"Cashin","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejrad.2020.109275_bib0105","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1634\/theoncologist.2015-0033","article-title":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstrom Macroglobulinemia as a paradigm","volume":"20","author":"Nishino","year":"2015","journal-title":"Oncologist."},{"key":"10.1016\/j.ejrad.2020.109275_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejrad.2020.109275_bib0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.03.006","article-title":"Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1","volume":"96","author":"Mekki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejrad.2020.109275_bib0120","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0125","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","article-title":"Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients","volume":"5","author":"Garcia-Neuer","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejrad.2020.109275_bib0135","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2020.109275_bib0140","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0145","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2217\/fon-2019-0102","article-title":"Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma","volume":"15","author":"Baba","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00026","article-title":"Drug-related pneumonitis in the era of precision cancer therapy","author":"Nishino","year":"2017","journal-title":"Jco Precis. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0155","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid."},{"key":"10.1016\/j.ejrad.2020.109275_bib0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","author":"Lee","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejrad.2020.109275_bib0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0170","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejrad.2020.109275_bib0175","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/j.cgh.2018.03.005","article-title":"A case of enteritis induced by nivolumab","volume":"17","author":"Kobayashi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0180","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1159\/000452403","article-title":"Ipilimumab-induced enteritis without colitis: a new challenge","volume":"9","author":"Messmer","year":"2016","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0185","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","article-title":"Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report","volume":"99","author":"Ikeuchi","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejrad.2020.109275_bib0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejrad.2020.109275_bib0200","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejrad.2020.109275_bib0205","first-page":"1462","article-title":"Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication","volume":"62","author":"Ganss","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejrad.2020.109275_bib0210","doi-asserted-by":"crossref","first-page":"Fso378","DOI":"10.2144\/fsoa-2018-0123","article-title":"Radiation recall pneumonitis in the setting of immunotherapy and radiation: a focused review","volume":"5","author":"McGovern","year":"2019","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.ejrad.2020.109275_bib0215","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2020.109275_bib0220","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2020.109275_bib0225","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ejrad.2020.109275_bib0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-019-0583-3","article-title":"Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features","volume":"7","author":"Schoenfeld","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejrad.2020.109275_bib0235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clinimag.2017.12.014","article-title":"Multimodality imaging of endocrine immune related adverse events: a primer for radiologists","volume":"50","author":"Alessandrino","year":"2018","journal-title":"Clin. Imaging"},{"key":"10.1016\/j.ejrad.2020.109275_bib0240","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0245","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejrad.2020.109275_bib0255","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejrad.2020.109275_bib0260","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X20304642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X20304642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:17:52Z","timestamp":1759994272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X20304642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"alternative-id":["S0720048X20304642"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2020.109275","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2020.109275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109275"}}